The androgenicity of progestins

The American Journal of Medicine

Volumn 98, Issue 1 SUPPL. 1, 1995, Pages

  Darney, Philip D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANE DERIVATIVE; ANDROSTANOLONE; DESOGESTREL; ESTROGEN; ETYNODIOL DIACETATE; GESTAGEN; GESTODENE; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; NANDROLONE DERIVATIVE; NORETHISTERONE; NORETYNODREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; PREGNANE DERIVATIVE; SEX HORMONE BINDING GLOBULIN;

ACNE; ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY RISK; GLUCOSE TOLERANCE; HIRSUTISM; HORMONE STRUCTURE; HUMAN; HYPERCOAGULABILITY; LIPOPROTEIN SYNTHESIS; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; WEIGHT GAIN;

BIOLOGY; CARBOHYDRATE METABOLIC EFFECTS; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--SIDE EFFECTS; CONTRACEPTIVE AGENTS, PROGESTIN--SIDE EFFECTS; CONTRACEPTIVE AGENTS--SIDE EFFECTS; FAMILY PLANNING; LIPID METABOLIC EFFECTS; LIPIDS; LITERATURE REVIEW; METABOLIC EFFECTS; PHYSIOLOGY;

ANDROGENS; FEMALE; HUMAN; PROGESTATIONAL HORMONES;

EID: 0028952384     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)80067-9     Document Type: Article

References (45)

1. Metabolism of levonorgestrel norethindrone, and structurally related contraceptive steroids
2. Progestogens and cardiovascular reac-tions associated with oral contraceptives and a comparison of the safety of 50 and 30-microgram oestrogen preparations
3. Progestagens and arterial disease—evidence from the Royal College of General Practitioners' study
4. Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Fin-land from 1975 to 1984
5. A prospective study of past use of oral contraceptive agents and the risk of cardiovascular dis-eases
6. Mortality among oral contraceptive users
7. Receptor binding and in vivo activities of the new progestins
8. New progestins in oral contraception
9. Serum steroid binding protein concen-trations and bioavailability of testosterone with oral contraceptives
10. Clinical evidence of the minimal andro-genic activity of norgestimate
11. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin total and free testosterone
12. Effect of two oral contraceptives containing 30 micrograms ethinyl estradiol and 75 micrograms gestodene or 150 micrograms desogestrel upon various hormonal parameters
13. Androgenic, oestrogenic and antioestrogenic effects of desogestrel and lynestrenol alone: effects of serum proteins, sex hormones and vaginal cytology
14. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol
15. Binding of progestogens to receptor proteins in MCF-7 cells
16. Clinical and hormonal effects of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene
17. A cross-over study of three oral contraceptives containing ethinyl oestradiol and either desogestrel or levonorgestrel
18. Serum total and unbound testosterone and sex hormone binding globulin in female acne patients treated with two different oral contraceptives
19. Effects of three Low-Dose Oral Contraceptive Combinations on Sex Hormone Binding Globulin, Corticosteroid Binding Globulin and Antithrombin III Activity in Healthy Women: Two Monophasic Desogestrel Combinations (Containing 0.020 or 0.030 mg Ethinylestradiol) and One Triphasic Levonorgestrel Combination
20. Clinical tolerance of a low-dose norgestimate-containing combination oral contraceptive (Cilest) in a West Germany multicenter study (Heidelberg Multicenter Oral Contraceptive Study)
21. Influence of a combination of desogestrel and ethinyl estradiol on acne vulgaris in women seeking contraception; results of an open non-comparative, multicenter trial
22. Clinical evaluation of a monophasic ethinyl estradiol/ desogestrel-containing oral contraceptive
23. Effects of desogestrel/ethinyl estra-diol in hirsutism and rogens and SHBG
24. Oral contraceptives containing desogestrel in hirsutism
25. The effects of desogestrel and ethinylestra-diol combination in normal and hyperandrogenic young girls: speculations on contra-ception in adolescence
26. Effect of desogestrel with 20 or 30 micrograms ethinyl estradiol in adolescents with hyperandrogenism
27. SBHG, CBG and ceruloplasmin changes with two low dose oral contraceptives
28. The efficacy and olerability of norgestimate/ ethinyl estradiol: results of an open multicenter study of 59, 701 women
29. Efficacy and Clinical Profile of a New Oral Contraceptive Containing Norgestimate: U.S. Clinical Trials
30. an innovative progestin
31. The interaction between sex hormone binding globulin and levonorgestrel released from Norplant, an implantable contraceptive
32. Sustained release contraceptives
33. Clinical results with subcutaneous implants containing 3-ketodesogestrel
34. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins
35. Comparison of two triphasic contracep-tives with different progestogens: effects on metabolism and coagulation proteins
36. Meta-bolic changes during treatment with two different progestogens
37. Comparison of two triphasic oral contracep-tives containing either gestodene or norethindrone: a randomized controlled trial
38. A Comparison Study of Lipid and Androgen Metabolism with Triphasic Oral Contraceptive Formulations Containing Norgestimate or Levonorgestrel
39. Clinical comparison of two low-dose oral contraceptives, Minulet Mercilon, in women over 30 years of age
40. Selectivity and minimal androgenicity of norgestimate in mono-phasic and triphasic oral contraceptives
41. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel
42. Clinical acceptability of monophasic gestodene
43. Efficacy and safety of triphasic DSG/EE
44. Two oral contraceptives, efficacy serum proteins lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination